Abstract

Background: Regarding the therapeutic target in asthma, super-responder status (SR) is a status without systemic corticosteroids. Recently, clinical remission (CR), being a status of prolonged absence of asthma symptoms without systemic corticosteroids and/or normal pulmonary function, has gained attention as a new therapeutic target in asthma. Here, we examined the percentage and features of asthma patients on treatment with dupilumab showing SR and CR.
Materials and methods: 49 asthma patients used subcutaneous dupilumab for > 1 year between April 2019 and November 2022. The status of SR and CR for 1 year was evaluated. Patients without any maintenance oral corticosteroids and exacerbations requiring systemic corticosteroids were classified as SR. CR was defined using three definitions based on changes in asthma symptoms and pulmonary function in addition to achieving SR for 1 year: CR without pulmonary function criteria (CR w/o F), fulfilment of asthma symptom improvement (asthma control questionnaire score < 0.75 or asthma control test score ≥ 23); and CR-70 or CR-80, pulmonary function improvement (%forced expiratory volume in 1 second ≥ 70% or ≥ 80%) in addition to achieving CR w/o F, respectively.
Results: 38 (77.6%), 22 (44.9%), 13 (26.5%), 12 (24.5%) of patients had SR, CR w/o F, CR-70, and CR-80, respectively. Severe eosinophilic chronic rhinosinusitis was significantly more found in patients with SR and CR based on all three definitions than in those without.
Conclusion: This study identified the percentage and features of patients on treatment with dupilumab showing SR and CR in a real-world setting. The outcome beyond CR on biologic treatment should be clarified.

Author Details

Authors

• Satoshi Hamada¹
• Eriko Ogino²
• Hirotaka Yasuba³

Departments

• ¹ Department of Advanced Medicine for Respiratory Failure, Graduate School of Medicine, Kyoto University,
• ² Kyoto Station-front Ear Nose and Allergy Clinic, and
• ³ Department of Airway Medicine, Mitsubishi Kyoto Hospital, Kyoto, Japan

Address

Satoshi Hamada, MD, PhD
Department of Advanced Medicine for Respiratory Failure
Graduate School of Medicine, Kyoto University
54 Shogoin Kawahara-cho
Sakyo-ku, Kyoto, 606-8507, Japan
Email: [email protected]

Citation